766
Granisetron hydrochloride (3 mg on days 1, 8, and 15) and dexamethasone (13.2 mg on day 1 and 6.6 mg on days 2, 3, 8, and 15) were used prior to irinotecan administration in both patients.
 both patients: Subject; Granisetron hydrochloride (3 mg on days 1, 8, and 15) and dexamethasone (13.2 mg on day 1 and 6.6 mg on days 2, 3, 8, and 15): Treatment; irinotecan: Treatment; Granisetron hydrochloride: Treatment.Drug; dexamethasone: Treatment.Drug; 3 mg: Treatment.Dosage; 13.2 mg: Treatment.Dosage; 6.6 mg: Treatment.Dosage; on day 1: Treatment.Freq; on days 1, 8, and 15: Treatment.Freq; on days 2, 3, 8, and 15: Treatment.Freq; dexamethasone: Combination.Drug; Granisetron hydrochloride: Combination.Drug
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: potential therapeutic event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Treatment.Time_elapsed, Subject.Disorder, Subject.Race, Treatment.Route, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 both patients: Subject; Granisetron hydrochloride (3 mg on days 1, 8, and 15) and dexamethasone (13.2 mg on day 1 and 6.6 mg on days 2, 3, 8, and 15): Treatment; irinotecan: Treatment; Granisetron hydrochloride: Treatment.Drug; dexamethasone: Treatment.Drug; 3 mg: Treatment.Dosage; 13.2 mg: Treatment.Dosage; 6.6 mg: Treatment.Dosage; on day 1: Treatment.Freq; on days 1, 8, and 15: Treatment.Freq; on days 2, 3, 8, and 15: Treatment.Freq; dexamethasone: Combination.Drug; Granisetron hydrochloride: Combination.Drug